Addition of bevacizumab to gefitinib plus chemotherapy as first-line therapy in EGFR L858R mutate advanced non-small cell lung cancer patients
The combination of bevacizumab, gefitinib, and chemotherapy significantly benefits patients with the L858R mutation in first-line PFS but not OS.
Authors
- Fengge Zhou (ORCID: https://orcid.org/0000-0001-7159-6647)
- Zhe Yang (ORCID: https://orcid.org/0000-0002-7018-0823)
- Yi Ding (ORCID: https://orcid.org/0000-0003-1356-6401)
- Jixian Li (ORCID: https://orcid.org/0000-0002-6880-7252)
- Xiang Zhan (ORCID: https://orcid.org/0000-0001-8823-743X)
- Jiaxin Li (ORCID: https://orcid.org/0000-0002-6115-6848)
- Alei Feng
- Lingli Lei
- Xiaomei Li
Institutions
- Hebei Medical University (CN)
- Shandong University (CN)
- Second Hospital of Shandong University (CN)
- Shandong Provincial Hospital (CN)
- Shandong First Medical University (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-10-08
- DOI
- https://doi.org/10.3389/fphar.2025.1503171
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Chinese Society of Clinical Oncology